Skip to main content

Table 1 The baseline and clinicopathologic characteristics of 184 patients with metastatic renal cell carcinoma

From: Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma

Variable

No. of patients (%)

Post-treatment hypoalbuminemia group (<36.4 g/L)

Normal post-treatment albumin level group (≥36.4 g/L)

P value

Sex

   

0.589

 Men

137 (74.5)

27 (71.1)

110 (75.3)

 

 Women

47 (25.5)

11 (28.9)

36 (24.7)

 

Age (years)

   

0.215

 <65

141 (76.6)

32 (84.2)

109 (74.7)

 

 ≥65

43 (23.4)

6 (15.8)

37 (25.3)

 

Pathologic type

   

0.060

 ccRCC

179 (97.3)

35 (92.1)

144 (98.6)

 

 nccRCC

5 (2.7)

3 (7.9)

2 (1.4)

 

History of nephrectomy

   

0.945

 Yes

146 (79.3)

30 (79.0)

116 (79.5)

 

 No

38 (20.7)

8 (21.0)

30 (20.5)

 

History of cytokine treatment

   

0.811

 Yes

66 (35.9)

13 (34.2)

53 (36.3)

 

 No

118 (64.1)

25 (65.8)

93 (63.7)

 

Fuhrman grade

   

<0.001

 1–2

104 (56.5)

9 (23.7)

95 (65.1)

 

 3–4

65 (35.3)

24 (63.2)

41 (28.1)

 

 Unknown

15 (8.2)

5 (13.1)

10 (6.8)

 

Number of metastatic sites

   

0.053

 1

130 (70.7)

22 (57.9)

108 (74.0)

 

 ≥2

54 (29.3)

16 (42.1)

38 (26.0)

 

Metastatic site

    

 Lung

137 (74.5)

33 (86.8)

104 (71.2)

0.050

 Lymph node

44 (23.9)

11 (29.0)

33 (22.6)

0.414

 Bone

20 (10.9)

0 (0.0)

20 (13.7)

0.034

 Liver

16 (8.7)

2 (5.3)

14 (9.6)

0.400

 Others

15 (8.2)

2 (5.3)

13 (8.9)

0.465

MSKCC risk category

   

0.072

 Favorable

83 (45.1)

12 (31.6)

71 (48.6)

 

 Intermediate

72 (39.1)

18 (47.4)

54 (37.0)

 

 Poor

29 (15.8)

8 (21.0)

21(14.4)

 

NLR

   

0.440

 <2.2

73 (39.7)

13 (34.2)

60 (41.1)

 

 ≥2.2

111 (60.3)

25 (65.8)

86 (58.9)

 

First-line therapy

   

0.149

 Sorafenib

112 (60.9)

27 (71.1)

85 (58.2)

 

 Sunitinib

72 (39.1)

11 (28.9)

61 (41.8)

 
  1. ccRCC, clear cell renal cell carcinoma; nccRCC, non-clear cell renal cell carcinoma; MSKCC, Memorial Sloan Kettering Cancer Center; NLR, neutrophil-to-lymphocyte ratio